Clinical trials: Stage 2 Hypertension
Difficult to Control Hypertension
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory…
- Trial name
- BOLD-HTN (NCT06343298)
- Testing
- MANP
- Where
- 23 sites in United States
- Volunteers
- 120 people
- Sponsor
- E-Star BioTech, LLC
Hypertension
Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker
A comparison of 2 different combinations of high blood pressure medications to treat hypertension
- Trial name
- NCT00185120
- Testing
- Olmesartan medoxomil, Hydroclorothiazide, Benazepril
- Where
- 20 sites in United States
- Volunteers
- 152 people
- Sponsor
- Daiichi Sankyo
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
A Phase 2 open label, dose escalation study to find the minimally and maximum effective dose (dose beyond which no further effect on PVR is seen) of inhaled nitric oxide generated by the GeNOsyl® System compared to placebo.
- Trial name
- PHiano (NCT01265888)
- Testing
- Inhaled Nitric Oxide
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Geno LLC
Open Angle Glaucoma, Ocular Hypertension
Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension
The goal of this clinical trial is to learn about the safety of Travoprost Ophthalmic Topical Cream and how well it works in lowering high intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular…
- Trial name
- NCT06152861
- Testing
- Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Glaukos Corporation
Hypertension
Rheos® Pivotal Trial
The purpose of this clinical trial is to demonstrate the efficacy and safety of the Rheos system in subjects with hypertension that are resistant to treatment with at least three anti-hypertension agents, one of which is a…
- Trial name
- NCT00442286
- Testing
- Rheos® Baroreflex Hypertension System
- Where
- 44 sites in United States, Germany and 1 more
- Volunteers
- 591 people
- Sponsor
- CVRx, Inc.
Primary Open-Angle Glaucoma, Ocular Hypertension
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
The objective of this Phase 2 study is to evaluate whether the Bimatoprost Ocular Insert is non-inferior to that of timolol ophthalmic solution (0.5%) at 12 weeks.
- Trial name
- NCT01915940
- Testing
- Bimatoprost, Timolol 0.5%
- Where
- 10 sites in United States
- Volunteers
- 169 people
- Sponsor
- ForSight Vision5, Inc.
Pulmonary Arterial Hypertension
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to <18 years of age with PAH World Health Organization (WHO)…
- Trial name
- MOONBEAM (NCT05587712)
- Testing
- Sotatercept
- Where
- 35 sites in United States, Australia and 10 more
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Diabetes
Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes
The purpose of this study was to evaluate the antihypertensive and antiglycemic effects, as well as the safety and tolerability of TAK-491 (azilsartan medoxomil), once daily (QD), in stage 1 hypertensive, type 2 diabetes mellitus…
- Trial name
- NCT01496430
- Testing
- Azilsartan medoxomil
- Where
- 68 sites in United States
- Volunteers
- 105 people
- Sponsor
- Takeda
Hypertension and Dyslipidemia
Study to Evaluate the Safety and Pharmacokinetics of CKD-331
Phase 1 study to evaluate the safety and pharmacokinetics of CKD-331 in healthy adult volunteers
- Trial name
- NCT05335044
- Testing
- CKD-331, EX5619
- Where
- South Korea
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics
Hypertension
A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension
A multicenter, randomized, double-blind, parallel, phase 2 study to explore the dose of HCP1803 in patients with essential hypertension
- Trial name
- HM_APOLLO (NCT04959305)
- Testing
- HCP1803-3, RLD2003, RLD2004
- Where
- South Korea
- Volunteers
- 245 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential Hypertension, Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-3" and "BR1019-2" in healthy volunteers
- Trial name
- NCT06636877
- Testing
- BR1019, BR1019-2, BR1019-3
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Pulmonary Hypertension
ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
The primary objective is to determine the effect of ambrisentan on exercise capacity in subjects with PAH.
- Trial name
- NCT00091598
- Testing
- Ambrisentan
- Where
- 46 sites in United States, Australia and 1 more
- Volunteers
- 372 people
- Sponsor
- Gilead Sciences
Essential Hypertension, Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus
- Trial name
- NCT06220773
- Testing
- BR1019A, BR1019B, BR1019C
- Where
- 3 sites in Indonesia, South Korea
- Volunteers
- 276 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Pulmonary Arterial Hypertension
Drug Interaction Between Ritonavir And Sitaxsentan
The study is to assess if sitaxsentan and ritonavir will affect the blood levels of each other when coadministered.
- Trial name
- NCT01251848
- Testing
- Sitaxentan, Ritonavir, Sitaxsentan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Primary Open Angle Glaucoma, Ocular Hypertension
Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure
The goal of this clinical trial is to test in patients with glaucoma and elevated pressure in the eye. The main questions it aims to answer are: • ability to lower pressure in the eye • safety in the eye and the body of patients…
- Trial name
- NCT06144918
- Testing
- SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Skye Bioscience, Inc.
Glaucoma
Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Trial name
- NCT07075718
- Testing
- Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- Glaukos Corporation
Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)
This is a randomized, double-blind, multi-center, placebo-controlled dose-ranging clinical trial of two IkT-001Pro doses in patients with PAH designed to assess safety, tolerability and efficacy.
- Trial name
- NCT06643143
- Testing
- IkT-001Pro
- Sponsor
- Inhibikase Therapeutics
Pulmonary Arterial Hypertension
Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension
Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-251 administered for 24 weeks in participants with pulmonary arterial hypertension (PAH)
- Trial name
- RELIEF-PAH (NCT03789643)
- Testing
- JTT-251
- Sponsor
- Shionogi Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, compared to…
- Trial name
- NCT06964191
- Testing
- PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- PolyActiva Pty Ltd